3-[2-(2-Nitrososulfanylpropanoylamino)acetyl]-1,3-thiazolidine-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[2-(2-Nitrososulfanylpropanoylamino)acetyl]-1,3-thiazolidine-4-carboxylic acid
• 化学式: C₉H₁₃N₃O₅S₂
• 分子量: 307.4
• InChiKey: NKVBEZCPQITVJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  167
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Use of nitric oxide adducts
  申请人：Stamler Jonathan

  公开号：US20070248676A1

  公开（公告）日：2007-10-25

  The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; coated per se on a surface of the medical device; directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.